🇺🇸 FDA
Pipeline program

TAR-0520 Gel

TARIAN 014

Phase 2 small_molecule active

Quick answer

TAR-0520 Gel for Taxanes-induced peripheral neuropathy is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Taxanes-induced peripheral neuropathy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials